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Abstract
p53 is critical in the normal response to a variety of cellular stresses including DNA damage and loss of p53 function is a
common feature of many cancers. In hematological malignancies, p53 deletion is less common than in solid malignancies
but is associated with poor prognosis and resistance to chemotherapy. Compared to their wild-type (WT) counterparts,
hematopoietic progenitor cells lacking p53 have a greater propensity to survive cytokine loss, in part, due to the failure to
transcribe Puma, a proapoptotic Bcl-2 family member. Using expression arrays, we have further characterized the
differences that distinguish p53
2/2 cells from WT myeloid cells in the presence of Interleukin-3 (IL-3) to determine if such
differences contribute to the increased clonogenicity and survival responses observed in p53
2/2 cells. We show that p53
2/2
cells have a deregulated intracellular signaling environment and display a more rapid and sustained response to IL-3. This
was accompanied by an increase in active ERK1/2 and a dependence on an intact MAP kinase signaling pathway.
Contrastingly, we find that p53
2/2 cells are independent on AKT for their survival. Thus, loss of p53 in myeloid cells results in
an altered transcriptional and kinase signaling environment that favors enhanced cytokine signaling.
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Introduction
p53 is a critical regulator of the response to DNA damage and
oncogenic stress. Loss of p53 function, through mutation or
deletion, is a frequent occurrence in human malignancies. In
hematological malignancies, p53 deletion, 17p-, is less common,
but is a poor prognostic feature. p53 functions to regulate several
pathways, including cell cycle arrest, DNA repair and apoptosis
through transcriptional upregulation of proapoptotic Bcl-2 genes,
in particular Puma/Bbc3 and Noxa [1,2,3,4,5,6,7]. Loss of p53
protects cells from p53-dependent apoptotic stimuli due to limited
Puma and Noxa transcriptional upregulation.
The induction of apoptosis is a key tumor suppressor function of
p53, particularly in those cells which acquire other oncogenic
lesions [8]. p53-dependent Puma upregulation has a central role in
this response, inducing apoptosis in the transformed cells [9].
Interestingly, in response to an acute DNA-damaging stress such
as ionizing radiation, p53-dependent upregulation of Puma may
actually contribute to tumor development in some models [10,11].
In this situation, p53-dependent apoptosis induces cell death in
thymic cells which have sustained DNA damage but not yet
acquired oncogenic mutations. This cell loss creates a niche into
which surviving cells with transforming mutations may proliferate.
It is increasingly apparent that p53 also has a critical role in
regulating the response to a wide variety of cellular stresses. For
example, we and others have shown that deletion of p53 can
protect cells against apoptosis induced by cytokine deprivation, in
particular Interleukin-3 (IL-3) deprivation [12,13]. These results
complement earlier observations from Lotem and Sachs [14], who
showed that untransformed hematopoietic progenitor cells from
p53
2/2 mice formed colonies in limiting doses of cytokine. p53-
deficient hematopoietic progenitor cells were also able to form
more colonies in the absence of IL-3 compared to wild-type (WT)
cells [12]. These experiments clearly suggest that p53 is involved in
modulating the sensitivity to cytokine with a loss of p53 increasing
viability and growth in the presence of limiting cytokine doses. The
p53 response is also coupled to cell death in the absence of
cytokine with a failure to upregulate Puma expression a likely
explanation for this [12]. Thus, in the presence of IL-3 receptor
signaling, a p53-dependent response modulates the sensitivity to
cytokine receptor activation and may also contribute to growth
and survival differences important for tumorigenesis.
To explore this further we compared the expression profiles of WT
cells and p53
2/2 IL-3 dependent cells [12], hereafter referred to as
FDM (Factor Dependent Myeloid) cells, in the presence or absence of
IL-3, using microarray analysis. Under normal culture conditions, p53
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compared to WT cells. Some of these differences are in genes that
regulate cytokine signaling, in particular genes such as SOCS1 and
SOCS3, and the cell cycle inhibitor p21. The different gene expression
profiles suggest that even under optimal growth conditions deletion of
p53 alters gene expression rendering cells more responsive to changes
in cytokine levels. This may in part explain our and others observation
that lower doses of IL-3 are required to maintain viability of p53
2/2
cells compared to WT cells [14]. In support of this hypothesis, we show
that MAP Kinase signaling is activated earlier and in a more sustained
manner in p53
2/2 cells after IL-3 stimulation. Interestingly, we also
observed that p53
2/2 c e l l st r e a t e dw i t ha nA K Ti n h i b i t o rw e r e
protected from cell death in comparison to WT cells indicating that
AKT activation is redundant. In comparison, p53
2/2 cells were
sensitive to an MEK inhibitor indicating that MAP Kinase signaling
was required for p53
2/2 viability.
Expression array analysis of IL-3 withdrawal responsive genes
by Signaling Pathway Impact Analysis (SPIA) of curated pathways
indicates that WT samples displayed an identifiable response with
pathways such as the JAK-STAT, Insulin and p53 signaling
pathways significantly altered. In contrast, the changes in gene
expression in p53
2/2 cells upon IL-3 withdrawal did not show the
alterations to downstream cytokine signaling. Thus, the down-
modulation of cytokine signaling on withdrawal of cytokine
appears to be p53-dependent.
Materials and Methods
Generation of IL-3 dependent FDM cells
Murine WT and p53
2/2 factor dependent myeloid (FDM) cells
were generated previously by HoxB8 transformation [12] and their
generation was approved by the animal ethics committee at the
Murdoch Children’s Research Institute (AEC 594) and Walter &
Eliza Hall Institute (2003.024). All FDM cells were cultured in
DMEM (low glucose; Gibco) supplemented with 10% fetal calf serum
(FCS; JRH Laboratories) plus 0.25 ng/mL IL-3 (R&D systems).
Expression array
Expression array was performed as previously described [12].
Briefly, RNA from three biological replicates per genotype was
isolated using Qiagen RNAeasy extraction kit according to the
manufacturer’s instruction. RNA was labeled, amplified and
hybridized to Illumina MouseWG-6 V1 Expression BeadChips
according to Illumina standard protocols. Samples were processed
at the Australian Genome Research Facility, Melbourne, Aus-
tralia. A total of 18 arrays comprising over 46,000 transcripts that
interrogates the whole mouse genome, were generated covering
three time points (0, 6, 18 hours after IL-3 deprivation), and each
time series repeated in triplicate with independent biological
samples (Gene Expression Omnibus: NCBI gene expression and
hybridization array data repository accession GSE18770).
Expression array analysis
The data were analyzed using the lumi package [15] from
Bioconductor [16] and R (R development core, http://www.R-
project.org).
Expression array quality assessment
The quality of the array series was assessed using the package
arrayQualityMetrics, which offers an extensive set of visualizations and
metrics for assessing microarray data quality [17]. Applied to this
dataset, arrayQualityMetrics indicates that although in general the data
are of good quality, one sample was considered to be an outlier and
hence was excluded from further analysis (arrayQualityMetrics).T h e
proportion of expressed probes for each arrayis represented in Table 1.
The empirical reliability of each array following a linear model
fit was estimated. A normexp-by-control background correction,
quantile normalization and log2 transformation was carried out.
Probes that failed to achieve a BeadStudio detection p value of
0.01 on any array were deemed to be not expressed, and hence
were removed from all subsequent analyses. Hierarchical cluster-
ing was carried out which is hierarchical cluster analysis on a set of
dissimilarities. These dissimilarities are a distance matrix comput-
ed by using the Manhattan distance on the expression data. A
linear model was fitted for each probe; subsequently differential
expression analysis was carried out.
Signaling Pathway Impact Analysis (SPIA)
For the signaling pathways available in KEGG (Kyoto
Encyclopedia of Genes and Genomes), the Signaling Pathway
Impact Analysis (SPIA) algorithm [18,19,20] was conducted. SPIA
uses information from differentially expressed genes and their fold
changes, as well as pathways topology in order to assess the
significance of the pathways in the condition under the study. At
time of writing, 80 pathways were available for searching. A false
discovery adjusted global p-value cut-off of 0.1 was chosen. A SPIA
analysis provides information on the KEGG pathway being
perturbed (the KEGG ID), the number of genes in the KEGG
pathway (pSize), the number of differentially expressed genes found
within the pathway (NDE), the False Discovery Rate (pGFdr), and
whether the pathway is activated or inhibited (Status).
Gene Set Enrichment Analysis (GSEA)
Broad GSEA software was used to analyze array results [21,22].
A mean-rank gene set test to analyze whether a set of genes is
highly ranked relative to other genes in terms of the residual
standard deviation for each gene taken from the linear model fitted
to the array. Genes were considered expressed in the array based
on their detection p-value.
Western blot analysis
Cells were lysed in RIPA buffer (150 mM NaCl, 50 mM
TrisHCl pH 7.4, 0.5% sodium deoxycholate (DOC), 0.1% SDS,
1% NP40, protease inhibitor cocktail, 5 mM ßglycerophosphate,
1 mM Na Molybdate, 2 mM Na pyrophosphate, 10 mM NaF).
Lysates were resolved by SDS-PAGE and immunoblotted with the
following antibodies: rabbit monoclonal anti-phospho Stat5 (Tyr
694; Cell Signaling), rabbit monoclonal anti-Stat5 (Cell Signaling),
rabbit polyclonal anti-phospho ERK1/2 (Thr 202/Tyr 204; Cell
Signaling), rabbit polyclonal anti-ERK1/2 (Cell Signaling), rabbit
monoclonal anti-phospho AKT (Ser 473; Cell Signaling), mouse
monoclonal anti-AKT (Cell Signaling), mouse monoclonal anti-
Table 1. Proportion of expressed probes for each array.
Genotype and hours withdrawn of IL-3 WT 0 h WT 6 h WT 18 h p53
2/2 0h p53
2/2 6h p53
2/2 18 h
Proportion of expressed probes 0.319 0.340 0.330 0.319 0.319 0.301
doi:10.1371/journal.pone.0031428.t001
p53-Dependent Pathways Regulated by IL-3
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Aldrich) and donkey polyclonal anti-rabbit IgG coupled to HRP
(Amersham).
Cell Viability Assays
IL-3 was removed by washing cells 3 times in PBS before being
cultured in DMEM/10% FCS with or without IL-3 (as indicated)
or treated with the AKT inhibitor VIII (Calbiochem) at 0, 0.1 or
0.5 ng/mL or a MEK inhibitor (U0126; Selleck chemicals) at 0,
40 or 200 nM. Cell viability was determined by staining cells with
Propidium Iodide (PI, 1 mg/mL; Sigma- Aldrich) followed by flow-
cytometric analysis (LSR II; Becton Dickinson).
Clonogenic survival assays
Clonogenic survival assays were performed as previously
described [23,24]. Briefly, 1610
4 cells/mL were cultured in
DMEM, 10% FCS with or without IL-3 at various concentrations.
After three days, cells were plated in 6-well plates in DMEM, 20%
FCS, 0.5 ng/mL IL-3, and 0.3% soft agar. After 14 days the
numbers of colonies were counted and expressed as a percentage
relative to the number of colonies generated per 1000 cells
cultured in IL-3. At least 3 independent clones of each genotype
were assayed in each experiment.
Results
Gene expression profile of WT and p53
2/2 FDM cells in
the presence of IL-3
Previously, we showed that the apoptotic response to cytokine
deprivation in immortalized IL-3 dependent myeloid cells (Factor
Dependent Myeloid or FDM cells) differed significantly between
cells derived from WT and p53
2/2 mice. Decreased Puma protein
levels in p53
2/2 cells contributed to the survival advantage
exhibited by these cells when starved of IL-3 [12]. We speculated
that p53-dependent transcription under non-stress conditions
(abundant IL-3) also contributed to the enhanced viability and
clonogenicity of p53
2/2 FDM cells. As previously described [12],
RNA samples from three independent clones each of WT and
p53
2/2 FDM cells, 0, 6 and 18 h after IL-3 withdrawal, were
analyzed using the Illumina MouseWG-6 Expression BeadChip
array. To extract the most significantly variant genes, we
considered that significantly differentially expressed genes had an
adjusted p-value of 0.1 or lower and a positive B statistic (1000
probes). In the presence of IL-3, 533 probes, representing 519
genes, showed significantly higher expression in the WT samples
compared to p53
2/2 samples and 467 probes representing 431
genes showed significantly reduced expression. The top 30 most
differentially expressed genes in WT and p53
2/2 samples are
shown in Figure 1A. Three members of the Suppressor of
Cytokine Signaling (SOCS) family, the SH2-containing protein,
CISH (also known as CIS or SOCS), SOCS1 and SOCS3 were
expressed at significantly higher levels in WT cells, compared to
p53
2/2 cells in the presence of IL-3. The SOCS family of proteins
are modulated by various cytokines including IL-2, IL-3, EPO and
G-CSF [25]. CISH functions to inhibit STAT5, in the presence of
IL-3, resulting in reduced activation of the JAK/STAT pathway
[26]. This raises the possibility that in the absence of p53
decreased CISH expression results in amplified IL-3 signaling. To
determine whether mRNA levels of SOCS1 and SOCS3 reflected
difference in protein expression, we probed lysates from 4
Figure 1. Differential gene expression in WT and p53
2/2 FDM samples. (A) RNA from three independent WT and p53
2/2 FDM cell lines were
analyzed with the use of the 6-chip Illumina expression array. The heatmap depicts the expression of the top 30 differentially expressed genes
according to the adjusted P value in WT and p53
2/2 samples. (B) Differentially expressed genes highly expressed in p53
2/2 compared to WT samples
with a logFC change of greater than 2 are shown. (C) Differentially expressed genes highly expressed in WT compared to p53
2/2 samples with a
logFC change of greater than 2 are shown. Asterisks show the p53-dependent gene CDKN1A (p21).
doi:10.1371/journal.pone.0031428.g001
p53-Dependent Pathways Regulated by IL-3
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2/2 cell lines with
antibodies to SOCS1 and SOCS3 (supplemental Figure S1A).
These data show that SOCS3 expression varies between cell lines
but does not show any consistent elevation in p53
2/2 cells.
Although SOCS1 expression was in fact higher in 2 of 4 p53
2/2
cell lines than in WT cell lines, these differences were not
consistent across all cell lines. In addition, we saw no consistent
differences in expression of IL-3 receptor components between
WT and p53
2/2 cell lines. These data suggest that differences in
the response to IL-3 signaling between WT and p53
2/2 cell lines is
not explained by expression levels of the IL-3 receptor, SOCS1 or
SOCS3.
To highlight the most prominent p53-dependent genes under
these conditions we selected genes with a LogFc of greater than 2,
since this would identify genes whose expression was much higher
in p53
2/2 than WT (potentially repressed by p53), and genes
whose expression was much higher in WT than p53
2/2
(potentially p53-induced) (Figure 1B and 1C). As expected, well-
described p53-dependent genes such as p21 (Cdkn1a) were
expressed at significantly lower levels in p53
2/2 FDM samples
compared to WT, indicating our system correctly identified known
p53-dependent genes. The genes most significantly over-expressed
by fold-change in p53
2/2 cells other than the Neomycin resistance
cassette, were Sphk1, Sphingosine Kinase 1 and Bcl11A suggesting
that these are normally down-regulated by p53. Down-regulation
of Sphk1 by p53 may be important for the apoptotic response as
Sphk1 expression is associated with increased survival [27] and has
been described in association with activated PI3K/AKT signaling
[28,29]. Bcl11A is a zinc-finger transcription factor, which is an
essential regulator of lymphopoiesis in mice, and its elevated
expression has been associated with some lymphoma patients in
humans [30,31,32,33]. Interestingly, Chronic Lymphocytic Leu-
kemia samples with gains at 2p16 locus (mapping to REL and
Bcl11a) are more frequent in samples which also bear 17p- (p53
loss) deletions [34,35]. The mechanism of this correlation is
unknown. In our FDM cells, although we identified an increase in
Bcl11a mRNA in p53 null samples, protein levels of Bcl11a were
not consistently elevated in multiple p53
2/2 FDM clones
compared to WT FDM clones cultured in the presence of IL-3
(Supplementary Figure S1B). Only subtle elevations of isoform 1
Figure 2. Pathway analysis of WT and p53
2/2 samples cultured in the presence of cytokine. (A) List of activated and inactivated pathways
identified by a Signaling Pathway Impact Analysis (SPIA) of array results from WT and p53
2/2 samples. The ID is the KEGG ID, pSize indicates the
number of genes in the KEGG pathway, NDE is the number of differentially expressed genes found within the pathway and pGFdr is the False
Discovery pathways (FDR,0.1). Significant pathways are shown. (B) The differentially expressed genes that account for the significant SPIA pathways
(from Figure 2A) are depicted by the heatmap. To the right of the heatmap, the dots indicate the pathways to which each gene contributes and
whether a gene is represented by several of the pathways.
doi:10.1371/journal.pone.0031428.g002
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2/2 FDM
clones.
Pathway Analysis
A Signaling Pathway Impact Analysis (SPIA) algorithm
[18,19,20] was performed for the pathways available in KEGG
(Kyoto Encyclopedia of Genes and Genomes). SPIA uses
information from a set of differentially expressed genes and their
fold changes, as well as pathways topology, to assess the potential
significance of a specific pathway being altered in a gene list
comparison. A false discovery adjusted global p-value cut-off of 0.1
was chosen. The fifteen pathways that were differentially
represented in p53
2/2 and WT FDM cells are listed in
Figure 2A. Since the same genes may be represented in many
different pathways, we were interested in which differentially
expressed genes accounted for the various pathway calls
(Figure 2B). A relatively small group of differentially expressed
genes accounted for the many activated or inactivated pathways.
For example, all isoforms of Calmodulin (Calm1, Calm2 and
Calm3) were represented in 7 different pathways, and were
decreased in p53
2/2 cells. In total, there were 73 differentially
expressed genes within these fifteen pathways, with 46 upregulated
in WT and 27 upregulated in p53 null samples. MAPK1
expression is represented in all but 2 of the 15 pathways, and
was upregulated in p53
2/2 cells. The Insulin signaling pathway
and MAPK signaling pathways were identified as pathways which
are selectively activated in p53
2/2 FDM cells suggesting these are
normally down-modulated by p53 (Figure 2B). The genes included
in these pathways are also known to be involved in cytokine signal
transduction such as IL-3 signaling and includes PIK3 gamma
(PIK3CG), SOCS1 and 3, MAPK1 and a-Raf. Activation of these
pathways in p53
2/2 FDM cells is consistent with a de-regulated
signal transduction environment and raises the possibility that
p53
2/2 cells are intrinsically more responsive to IL-3 and other
cytokines.
p53-dependent gene family enrichment in FDM samples
Gene Set Enrichment Analysis (GSEA) was done to compare
families of genes whose expression most differed between WT and
p53
2/2 FDM cells. The analysis was performed on the listed gene
families in Figure 3A [36,37,38,39,40,41]. The results indicated
that the gene families most different between WT to p53
2/2 FDM
samples were the tumor suppressors, kinases and transcription
factors. The logFC changes of each of individual differentially
expressed kinases are shown in Figure 3B. SGK1 (serum/
glucocorticoid kinase 1), and RIPK3 were expressed at approx-
Figure 3. Gene set enrichment analysis of WT and p53
2/2 expression array data. (A) Gene Set Enrichment Analysis (GSEA) of the WT and
p53
2/2 gene lists at the various time points. GSEA was conducted using all genes that were considered expressed in the array, based on their
detection p-value. A p-value of less than 0.05 was considered significant. (B) (C) Each diamond represents an individual probe for significantly
differentially expressed kinases (B) or transcription factors (C) in WT and p53
2/2 FDM cells cultured in IL-3.
doi:10.1371/journal.pone.0031428.g003
p53-Dependent Pathways Regulated by IL-3
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2/2 cells, suggesting p53
functions to regulate the expression of these kinases under
physiological conditions. However, RIPK3 protein levels in p53
null lysates were higher than seen in WT cells in 2 of 4 cell lines
(Supplemental Figure S1A). SGK1 is a serine-threonine kinase
related to AKT/PKB involved in transducing cytokine-dependent
survival signals [42] and like Sphk1 its down-regulation may be
important for an apoptotic response. In contrast, RIPK3 is a
kinase involved in necroptosis activated by TNF Receptor Family
signaling.
As mentioned above, Bcl11a was significantly upregulated in
p53
2/2 samples. In WT samples, the lineage-specific transcription
factor GFI1 was expressed at approximately 2-fold greater levels
relative to p53
2/2 cells suggesting that p53 levels may contribute
lineage choices. GFI1 may repress hematopoietic colony formation
and Bcl11A over-expression is associated with proliferative signals
and some AML subtypes [43,44]. Together, these data suggest
that a combination of an activated intracellular signaling
environment, combined with the expression of transcription
factors which favor clonogenic proliferation, contribute to the
survival and proliferative advantages observed in p53
2/2 cells.
FDM transcriptional response to cytokine withdrawal
We also extended the analysis of changes in gene expression in
WT and p53
2/2 FDM cells after IL-3 deprivation beyond the
analysis of Bcl-2 family members we have previously published
[12]. We used a linear model to determine which genes were
differentially expressed in WT or p53
2/2 at 0 h compared to 6 h
and 6 h compared to 18 h post cytokine withdrawal (with the
resulting t-statistics classifying genes as either up, down or not
significant).
The pathways most affected by 6 h of IL-3 withdrawal were
identified by SPIA KEGG analysis (Figure 4A and B). As
anticipated, the JAK/STAT, Insulin and p53 signaling pathways
were the top 3 pathways identified by SPIA to be responding to
IL-3 withdrawal. This type of analysis is not a definitive indication
of signaling kinase pathway activation, since the activity of such
pathways is dictated by events other than just gene transcription.
However, it is interesting that p53-dependent pathways were
identified as inactivated in this analysis, indicating p53-dependent
transcription contributes to the normal response to IL-3 signaling,
as well as the apoptotic response to IL-3 deprivation.
In contrast, the transcriptional differences observed p53
2/2
FDM samples assayed after 6 h of IL-3 deprivation did not cluster
in the same SPIA pathways as WT cells (Figure 4B). By 18 h, only
two KEGG pathways in the p53 null cell lines were activated
(Figure 4 and Supplementary Figure S2).
Increased sensitivity of p53
2/2 FDM cells to IL-3
We wanted to determine if the altered pathway activation or
inhibition revealed by gene expression profiling translated into
detectable differences in cellular responses to IL-3 signaling. One
prediction was that p53
2/2 cells would initiate IL-3 receptor
signaling at lower concentrations of IL-3 than WT cells. To test
this, we compared the viability of WT and p53
2/2 FDM cells in
decreasing concentrations of IL-3 ligand in both viability and
clonogenic assays (Figure 5A and 5B). At all except the highest
concentrations of IL-3 used, more p53
2/2 FDM cells were viable
than WT cells (Figure 5A). After WT or p53
2/2 FDM cells were
cultured in limiting IL-3 doses for three days they were plated in
soft agar containing abundant IL-3 (Figure 5B). In this clonogenic
assay, p53
2/2 cells were able to form more colonies than WT cells
at limiting IL-3 concentrations. This suggests that IL-3 can
transduce survival signals in p53-deleted cells at many fold lower
concentrations that in WT cells.
To determine if differential activation of cytokine signaling
pathways was occurring in p53
2/2 FDM cells after IL-3
stimulation, lysates from cells stimulated with various concentra-
tions of IL-3 after a period of IL-3 deprivation were probed with
antibodies to detect activation of the signaling kinases AKT, ERK
and STAT5 (Figure 5C). The most consistent difference observed
was that ERK1/2 phosphorylation occurred in response to lower
concentrations of IL-3 in p53
2/2 FDM cells (see also Supple-
mentary Figure S3). This was consistent with the array data
showing higher ERK2 (MAPK1) mRNA levels of in p53
2/2 FDM
cells and pathway analysis which suggested activation of the
MAPK pathway. There were no differences in total ERK1/2
levels between WT and p53
2/2 cells (Figure 5C). This data
indicates that loss of p53 resulted in higher levels of phosphorylated
ERK1/2 and ERK1/2 activation occurred in response to lower
IL-3 ligand concentrations. As transient activation of the ERK/
MAPK pathway can have profound effects on cellular response
compared to prolonged activation [45], loss of p53 may sensitize
cells to transient activation of this pathway leading to a substantial
increase in cell survival compared to WT cells.
AKT activation, as indicated by phosphorylation of serine 473
after IL-3 stimulation, was comparable between WT and p53
2/2
cells, or even slightly blunted in p53
2/2 cells (Figure 5C). This
suggested the possibility ERK activation was relatively more
important in p53
2/2 cells than in WT cells. We treated WT and
p53
2/2 FDM cells, cultured in the presence or absence of IL-3,
with increasing concentrations of an AKT or a MEK inhibitor to
determine whether p53
2/2 and WT cells had altered susceptibility
to apoptosis induced by these drugs. In response to the AKT
inhibitor, WT cells showed a dose-dependent decrease in viability
in the presence of IL-3, which was exacerbated by IL-3
deprivation. Intriguingly, p53
2/2 cells were highly resistant to
cell death induced by AKT inhibition, in the presence or absence
of IL-3. The withdrawal of IL-3 resulted in the death of
approximately 15% of p53
2/2 FDM cells, but this was not
significantly increased by AKT inhibition (Figure 5C). In contrast,
the reduction of p53
2/2 FDM cell viability was similar to the
response of WT cells (Figure 5D). To determine whether AKT
inhibition also affected ERK1/2 phosphorylation, or if MEK
inhibition affected AKT phosphorylation, we probed western blots
of lysates from cells treated with either inhibitor for phosphory-
lated AKT or ERK1/2 (Supplemental Figure S4). There was no
evidence to indicate that AKT inhibitor had an impact on ERK1/
2 phosphorylation or the reverse. AKT inhibition caused an
increase in Puma expression in WT but not p53 null cells. Puma is
normally upregulated in response to IL-3 deprivation [12]. It is not
Figure 4. Differential pathway expression in WT samples after IL-3 loss. (A) Three independent WT and p53
2/2 FDM cell lines were culture
with or without IL-3 for 6 h. RNA was extracted and expression array was performed as in Figure 1A. The heat map shows significant changes in
expression after IL-3 deprivation in WT cells and dots indicate the various SPIA pathways these represent. 31 differentially expressed genes were
active in these pathways, with 24 being highly expressed at time zero and 12 highly expressed at 6 h IL-3 withdrawal. Significant pathways are shown
(FDR,0.1). (B) Comparison of SPIA of array results from WT and p53
2/2 samples after IL-3 withdrawal. The ID is the KEGG ID, pSize indicates the
number of genes in the KEGG pathway, NDE is the number of differentially expressed genes found within the pathway and pGFdr is the False
Discovery pathways (FDR,0.1). Significant pathways are shown.
doi:10.1371/journal.pone.0031428.g004
p53-Dependent Pathways Regulated by IL-3
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upregulation. This suggests that in this model there no crosstalk
between these two pathways. Taken together, these results suggest
that IL-3 dependent FDM cells lacking p53 no longer require
AKT signaling to maintain viability, but are, in part at least,
dependent on ERK1/2 signaling. This suggests further that
regulation of AKT activation in response to IL-3 receptor
signaling is p53-dependent.
Figure 5. Analysis of the IL-3 signaling pathway in WT and p53
2/2 FDM cells. (A) Independently generated WT and p53
2/2 FDM cell lines
(n=number of cell lines) were cultured in the indicated concentrations of IL-3 for 72 hours. Viability was determined using Propidium iodide (PI)
exclusion detected by flow cytometry. Results show the mean +/2 SEM of 3 independent experiments. (B) WT and p53
2/2 independent FDM cell
lines (n=number of cell lines) were cultured in the indicated concentrations of IL-3 doses for 72 hours and then plated in soft agar with abundant IL-
3. The number of colonies was counted after 14 days and the clonogenicity (relative to the number of colonies generated in 500 pg/ml IL-3)
calculated. Results show the mean +/2 SEM of 2 independent experiments. (C) Lysates were generated from WT pr p53
2/2 FDM cells following
stimulation with the indicated concentrations of IL-3 after 16 hours of IL-3 deprivation. Lysates were resolved by SDS-PAGE and immunoblotted with
antibodies specific to the indicated proteins. (D) Independent WT and p53
2/2 FDM cell lines (n=number of cell lines) were treated for 24 h with an
AKT inhibitor (AKTi) in the presence or absence of IL-3. Viability was determined by flow cytometric analysis of PI exclusion. Results show the mean +/
2 SEM of 2 independent experiments. (E) Independent WT and p53
2/2 FDM cell lines (n=number of cell lines) were treated for 24 h with a MEK
inhibitor (MEKi) in the presence or absence of IL-3. Viability was determined by flow cytometric analysis of PI exclusion. Results show the mean
+/2 SEM of 4 independent experiments.
doi:10.1371/journal.pone.0031428.g005
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Although loss of function mutations or deletions affecting p53 is
frequent in many tumors, it is relatively rare in de novo AML [46]
and strongly associated with poorer prognosis. One possible
explanation is that p53-dependent proapoptotic proteins such as
Puma are important predictors of the responsiveness of many
cancer types, including myeloid malignancies, to chemotherapeu-
tic drugs [47]. However, it is also the case that hematopoietic
progenitor cells lacking p53 have a greater capacity for clonal
proliferation in the absence of any apoptotic stimuli [12]. Our data
demonstrates that deletion of p53 results in substantial differences
in mRNA expression profiles in cells under normal culture
conditions, and that the cell biological correlates of these
expression differences manifest as enhanced survival in limiting
doses of IL-3 and an amplified signaling response to IL-3
stimulation. This altered response to growth factor signaling may
contribute to tumorigenesis and altered responses to treatment
observed in the absence of p53.
In this study we did not focus on p53-dependent regulation of
apoptosis. We, and others, have shown that p53-dependent
upregulation of Puma and Noxa is essential for normal apoptosis
in response to p53-dependent death stimuli [3,4,6,23,48]. At the
same time, it has been elegantly demonstrated that the failure of
cells to undergo apoptosis does not account for all of the oncogenic
effects of loss of p53 function [8]. Indeed, in T-cell lymphoma
induced by irradiation, p53-dependent apoptosis was required for
tumor development, by removing cells and creating a niche in
which malignant cells could proliferate [10,11].
We sought to determine how p53 null myeloid cells differed
from their WT counterparts in the absence of an apoptotic
stimulus, and how such differences might contribute to the
oncogenic effects of p53 deletion. Expression levels of intracellular
kinases such as MAPK and secondary messenger molecules such
as the calmodulins suggested that p53
2/2 hematopoietic cells have
activated signal transduction pathways compared to WT cells.
However, expression levels alone do not prove the activation of
such pathways, nor whether there is any measurable effect on cell
behavior. Strikingly, ERK1/2 was more rapidly phosphorylated at
lower IL-3 concentrations in cells without p53. This is an
indication that MAPK signaling pathways are more readily
activated in p53
2/2 cells. It seems probable that a number of
factors, other than the expression levels of kinases, contribute to
this phenomenon. For example, p53
2/2 cells also expressed lower
levels of SOCS mRNA and higher levels of RIPK3 which may
contribute to cytokine receptor signaling. It is important to note
that these mRNA levels did not necessarily correlate with
consistent differences in protein expression, emphasizing the
importance of validating expression array experiments at a
pathway level as well as validating individual proteins. Further,
it is also apparent that variations in mRNA expression levels
between WT and p53
2/2 cells do not necessarily reflect
differences in p53 response genes. It is likely that many of the
observed differences arise because of adaptation to the lack of p53,
triggered by deregulation of a smaller number of direct p53
response genes.
Activation of PI3K and AKT is part of the IL-3 receptor
signaling pathways which regulate cell viability in response to IL-3
signaling [49]. Our pathway analyses indicated that PI3K
expression levels were lower in p53
2/2 FDM cells than WT cells.
When we looked for AKT activation in response to IL-3
stimulation, we observed that AKT was phosphorylated in p53
null cells similarly to WT cells. However, the resistance of p53
2/2
FDM cells to apoptosis induced by AKT inhibition suggests that
AKT activation is not required for IL-3 survival signaling in
p53
2/2 cells. AKT activation and p53 regulation are linked by
experimental evidence showing the E3 ubiquitin ligase which
regulates p53 stability, MDM2, is itself a substrate of AKT [50].
When cytokine receptor activation results in PI3K/AKT activa-
tion, MDM2 is phosphorylated and stabilized, resulting in p53
poly-ubiquitination and proteasomal degradation. Our data, and
that of others, suggests that the anti-apoptotic functions of AKT,
particularly in the context of IL-3 deprivation or deprivation of
metabolic substrates such as glucose, depend critically on p53. In
the absence of p53, this pathway becomes redundant. Thus, we
conclude that p53 plays an important role in the regulation of
signal transduction pathways activated by cytokines such as IL-3.
Interestingly, when p53
2/2 cells were treated with a MEK
inhibitor, they underwent apoptosis similar to WT cells. This
indicates that cells lacking p53 retain a dependence on MAP kinase
signaling, which is supported by the increased ERK1/2 phos-
phorylation in these cells. Proteomic analysis of Acute Myeloid
Leukemia samples has indicated that patients with higher levels of
p53 (which often is indicative of p53 mutation) also had abundant
ERK2 [51]. It is well recognized that loss of p53 is a poor
prognostic feature in hematological malignancy, at least in part
because cells lacking functional p53 do not activate apoptosis
pathways in response to chemotherapeutic drugs [52]. Our data
suggest that an alternative treatment strategy in p53-deleted
myeloid tumors would be the use of MAP kinase inhibitors. Our
data further suggest targeting of the PI3K/AKT pathway is
unlikely to be a successful therapeutic option where p53 is deleted
or mutated.
Supporting Information
Figure S1 Protein expression of SOCS1, SOCS3, RIPK3,
ß common chain, IL-3 a chain and Bcl11a in WT and
p53
2/2 FDM cells. (A and B) Lysates were extracted from
multiple clones of WT or p53
2/2 FDM cells cultured in IL-3.
Lysates were resolved by SDS-PAGE and immunoblotted with
antibodies specific the indicated proteins. ßactin is shown as a
loading control. (A) Two exposures of ß common are shown to
demonstrate expression in WT cell line 4 and p53
2/2 cell line 1.
(B) Bcl11a isoforms molecular weight are as follows, 1–84 kda, 2–
47 kda, 3–27 kda, 4–45 kda, 5–27 kda, 6–21 kda, 7–14 kda, 8–
53 kda.
(TIF)
Figure S2 Differential pathway expression in p53
2/2
samples after IL-3 loss. p53
2/2 FDM cell clones were
withdrawn of IL-3 for 6 or 18 h were analyzed by SPIA.
Significant pathways are shown (FDR,0.1).
(TIF)
Figure S3 ERK activation after IL-3 stimulation of WT
and p53
2/2 FDM cells. Lysates were extracted from WT pr
p53
2/2 FDM cells cultured in the absence of IL-3 for 16 h
followed by a 15 minute IL-3 re-addition at various concentrations
(as indicated). Lysates were resolved by SDS-PAGE and
immunoblotted with antibodies specific to phospho-ERK, total
ERK and ßactin.
(TIF)
Figure S4 AKT inhibition does not alter ERK1/2
phosphorylation and MEK inhibition does not affect
AKT phosphorylation. Lysates were extracted from cells
treated with either AKTi or MEKi and resolved on SDS-PAGE
and immunoblotted with the indicated antibodies. The predom-
p53-Dependent Pathways Regulated by IL-3
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Puma band. ßactin is shown as a loading control.
(TIF)
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